ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data
December 8, 2015Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology
Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
Strong cancer trial data for Janssen at ASH 2015
December 8, 2015Research and Development Cancer, Janssen, darzalex, imbruvica, oncology
Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …
Sandoz announces biosimilar successes
December 8, 2015Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim
Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …
Lilly pulls plug on basal insulin Peglispro
December 8, 2015Manufacturing and Production R&D, basal insulin peglispro, diabetes, lilly, peglispro, phase III failure
Lilly has decided to pull out of filing its diabetes drug basal insulin peglispro, after failing to convince regulators and …
Pharma companies ‘among happiest places to work’
December 8, 2015Manufacturing and Production Jobs, careers, employee satisfaction, pharma jobs, recruitment
Five pharmaceutical companies have placed in a top 50 of the happiest companies in America listing, based on reviews by …
Takeda’s Ninlaro extends myeloma survival in trial
December 7, 2015Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma
Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …
MSD’s Keytruda shows promise in multiple myeloma
December 7, 2015Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab
MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …
Featured Market Report: Atopic Dermatitis (eczema) Forecast in 17 Major Markets
December 7, 2015Manufacturing and Production, Research and Development Black Swan, eczema
Featured Market Report: Forecast Report on Atopic Dermatitis (eczema) in 17 Major Markets Black Swan’s report on Atopic Dermatitis, also …
Five benefits and challenges of the Pfizer/Allergan mega-merger
December 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Pfizer, acquisitions, mergers, takeovers
Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, …
Late-stage failure for Merck and Threshold cancer drug
December 7, 2015Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma
Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …
Mylan receives court summons from US Department of Justice
December 7, 2015Sales and Marketing Drug pricing, Justice department, Mylan, US Department of Justice, generics, investigation, subpoena
The US Department of Justice has contacted Mylan to make enquiries about the company’s pricing structure for antibiotic, doxycycline. Mylan …
Takeda reveals five-year Adcetris survival data
December 6, 2015Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology
Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …
Amgen’s Kyprolis doubles Velcade benefit in head-to-head study
December 5, 2015Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma
Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
ALG makes senior hires to increase global growth
December 4, 2015Manufacturing and Production, Sales and Marketing
Medical products company ALG has hired Matt Guixe as chief operating officer and Jackie Fisher as chief financial officer. Guixe …
Pfizer to close UK R&D site in surprise move
December 4, 2015Research and Development, Sales and Marketing Pfizer
Two weeks after its $160 billion buyout of botox-maker Allergan, Pfizer has announced that it is to close a UK …
New regulatory submissions for AbbVie and Novo Nordisk
December 4, 2015Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart
AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …
OBN appoints Dr John Harris as chief executive
December 4, 2015Medical Communications, Sales and Marketing OBN
OBN, the membership organisation supporting the UK’s emerging life sciences companies, has appointed Dr John Harris as its new chief executive, replacing …
Teva strips $1 billion worth of assets to clear Allergan deal
December 4, 2015Medical Communications, Sales and Marketing Allergan, Teva, acquisitions, divestments, mergers
Teva Pharmaceuticals is thought to be in the process of stripping nearly $1 billion worth of assets to address antitrust …
NICE backtracks on Novartis Farydak decision
December 4, 2015Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat
NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …
Cancer drugs prices vary up to 388% between high-income countries
December 4, 2015Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
